Showing results (91-100 of 120) with videos related to
Sort By:
Pageof 12
Transfusion Clinique Et Biologique : Journal De La Societe Francaise De Transfusion Sanguine|August 14, 2001
Non-myeloablative hematopoietic stem cell transplantationM Maris, B M Sandmaier, D G Maloney, et al.Bone Marrow Transplantation|October 11, 2001
Autologous stem cell transplantation for non-Hodgkin's lymphoma: comparison of radiation-based and chemotherapy-only preparative regimensF Gutierrez-Delgado, D G Maloney, O W Press, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2000
Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatmentT A Davis, A J Grillo-López, C A White, et al.Leukemia|March 18, 2005
High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantationF Baron, M B Maris, B E Storer, et al.Nature Medicine|February 1, 1996
T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patientsS R Riddell, M Elliott, D A Lewinsohn, et al.Blood|December 10, 1999
Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantationL A Holmberg, M Boeckh, H Hooper, et al.The Journal of Experimental Medicine|January 10, 2001
The immunogenicity of a new human minor histocompatibility antigen results from differential antigen processingA G Brickner, E H Warren, J A Caldwell, et al.British Journal of Haematology|February 24, 2005
Allogeneic peripheral blood stem cell graft composition affects early T-cell chimaerism and later clinical outcomes after non-myeloablative conditioningJ P Panse, S Heimfeld, K A Guthrie, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 31, 2009
Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group StudyJ W Sweetenham, B Goldman, M L LeBlanc, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximabT A Davis, C A White, A J Grillo-López, et al.Pageof 12